ADMA Biologics, Inc.
ADMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the. At a $1.85B market cap, ADMA Biologics, Inc. ranks as a small-cap company within healthcare. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Market Cap
$1.85B
Beta
0.82
P/E (TTM)
11.74
P/E (Fwd)
7.55
EPS (TTM)
$0.68
EPS (Fwd)
$1.06
ROE
43.3%
ROA
22.0%
Cash
$55.92B
Total Debt
$97.67B
Free CF
$58.4M
52W Change
-60.9%
Annual Financials
Cash vs Debt
ADMA Biologics, Inc. carries $97.67B in total debt against $55.92B in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $58.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 43.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.0% further supports the picture of efficient asset utilization. Revenue has grown from $154.1M (2022) to $510.2M (2025), reflecting a 231% increase over the period.
As with any equity investment, ADMA carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ADMA.